Coherus BioSciences (CHRS) Misses Q2 EPS by 8c
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.42 +7.58%
Financial Fact:
Occupancy and buying expenses: 81.34M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Occupancy and buying expenses: 81.34M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($0.34), $0.08 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $10.25 million versus the consensus estimate of $10.16 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- loanDepot receives NYSE non-compliance notice over stock price
- Hinge Health signs $86M office lease in San Francisco
- Myriad Uranium completes acquisition of Rush Rare Metals
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
